Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Summary

This study will explore whether defactinib (a FAK inhibitor) can be safely and tolerably combined with pembrolizumab (a PD-1 inhibitor) and will look for early indications of improved anticancer immunotherapy. It will focus on three key cancers, all in clear need of improved therapies - NSCLC, pancreatic cancer and mesothelioma.

Conditions

• Carcinoma, Non-small-cell Lung
• Mesothelioma
• Pancreatic Neoplasms

Interventions

DRUG

Defactinib

cross reference with arm/group descriptions

DRUG

Pembrolizumab

cross reference with arm/group descriptions

Sponsors & Collaborators

• University of Glasgow

  collaborator OTHER

• Cancer Research UK

  collaborator OTHER

• Merck Sharp & Dohme LLC

  collaborator INDUSTRY

• Verastem, Inc.

  collaborator INDUSTRY

• University of Edinburgh

  collaborator OTHER

• University of Southampton

  collaborator OTHER

• University of Leicester

  collaborator OTHER

• Queen's University, Belfast

  collaborator OTHER

• NHS Greater Glasgow and Clyde

  lead OTHER

Principal Investigators

• Stefan Symeonides · Edinburgh Cancer Research Centre, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XR

• Jeff Evans · Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN

• Christian Ottensmeier · Cancer Research UK Centre, Southampton University Hospitals and University of Southampton, Southampton SO16 6YD

• Dean Fennell · Department of Cancer Studies, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LX

• Vicky Coyle · Belfast Health and Social Care Trust, Cancer Centre, Lisburn Road, Belfast BT9 7BL

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-07-04

Primary Completion

2019-05-31

Completion

2021-12-31

Countries

• United Kingdom

Study Locations